author-photo

William L. Ince

Memorial Sloan Kettering Cancer Center

6

Papers

1977

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

2009 Oncologist
Show All
- Source
- Cite
- Save
Citations (220)
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1343)
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

2005 Journal of the National Cancer Institute
Show All
- Source
- Cite
- Save
Citations (294)
COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas

2004 Cancer Research
Show All
- Source
- Cite
- Save
Citations (118)
150 Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer

2004 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (2)
414 Correlation of mutations in EGFR with clinical outcomes in NSCLC patients treated with erlotinib

2004 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)